FV This Stock Should Be On Your Radar: It’s Selling At A 10% Discount And Rated A “Buy”

But I also think Morningstar is awfully conservative here. Averaging the three numbers out gives us a final valuation of $262.57, which would indicate the stock is possibly 10% undervalued. Bottom line: Amgen, Inc. (AMGN) is a world-class biotechnology company that should naturally benefit from large, long-term demographic tailwinds. With a market-beating dividend, double-digit dividend growth, a moderate payout ratio, more than a decade straight of dividend raises, and the potential that shares are 10% undervalued, this stock should be on every dividend growth investor’s radar right now.

Video Length: 00:10:16

1 2
View single page >> |

Disclaimer: Please consult with a licensed investment professional before investing any of your money. Never invest in a security or idea featured on this channel unless you can afford to lose ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.